Xantogranuloma órbito-palpebral: relato de caso

Xantogranuloma é doença histiocítica, caracterizada por lesões amareladas na pele ou na derme, acompanhadas ou não de alterações hematológicas ou neoplasias. O objetivo deste é relatar o caso de uma mulher de 39 anos, com queixa de inchaço progressivo nas pálpebras superiores, há 6 anos, indolor, sem alterações sistêmicas. O exame histológico mostrou infiltração maciça da pele, tecido muscular e gordura orbitária por histiócitos xantomatosos e abundantes células gigantes do tipo Touton. O diagnóstico foi de xantogranuloma do adulto. Os autores comentam os diagnósticos diferenciais, assim como a necessidade de exames periódicos, devido ao risco de associação com doenças sistêmicas malignas.Xantogranuloma is a histiocytic disease, characterized by yellowish lesions affecting the epidermis or the dermis, with or without hematological abnormalities and malignancy. The purpose of this paper is to report a 39-year-old woman with bilateral, progressive, painless swelling in both eyelids and anterior orbit, onset 6 years ago, with no systemic alterations. Histology of the excised tissue showed dermis, muscles and orbital fat with xantomatous histiocytes and Touton giant cells. The diagnosis was xantogranuloma of the adult. The authors call attention to other differential diagnosis and the necessity of periodical examinations because of the possibility of associated malignancies and systemic diseases

Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy

Background: The treatment of carcinoma of unknown primary based on histopathology and immunohistochemistry is generally chemotherapy. The use of molecular markers, genetic profiling platforms, and personalized medicine is under active investigation. Case Report: We report the case of a 56-year-old patient who presented to medical attention with palpable axillary adenopathy. Biopsy confirmed poorly differentiated adenocarcinoma. Formal staging revealed extensive metastatic disease to bone and liver. Initial chemotherapy proved ineffective. We describe the diagnostic evaluation, treatment, and achievement of durable remission using a novel sorafenib-based drug combination that was chosen through the application of a functional analytic laboratory platform. Conclusion: The clinical management of patients with carcinoma of unknown primary continues to present a considerable challenge for practicing oncologists. Laboratory platforms capable of examining cellular response to injury, growth factor withdrawal, and cytotoxic insult at the level of cellular function may provide insights for drug selection in this patient population

Additional file 1 of Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology

Additional file 1: Table S1. Profile of the panelists (n = 27) and of the SBM affiliated breast surgeons (n = 214) who participated in the survey

Additional file 5 of Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology

Additional file 5: Table S5. Summary of the consensus among the SBM affiliated breast surgeons

Additional file 7 of Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology

Additional file 7: Table S7.1. Comparison between the panelists and the SBM affiliated breast surgeons regarding the questions related to diagnosis. Table S7.2. Comparison between the panelists and the SBM affiliated breast surgeons regarding the questions related to surgery. Table S7.3. Comparison between the panelists and the SBM affiliated breast surgeons regarding the questions related to radiotherapy. Table S7.4. Comparison between the panelists and the SBM affiliated breast surgeons regarding the questions related to systemic treatment